Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on acute events in patients with acute myocardial infarction: multicenter randomized controlled trial

Trial Profile

Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on acute events in patients with acute myocardial infarction: multicenter randomized controlled trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Evolocumab (Primary) ; Pitavastatin
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top